Alnylam Pharmaceuticals, Inc. - Common Stock - Nakit Akışı (NASDAQ:ALNY)

Financials

İşletme faaliyetlerinden elde edilen nakit -614.96 M-641.69 M-541.27 M104.16 M-8.31 M524.08 M 712.9 M Yatırım faaliyetlerinden elde edilen nakit -435.52 M-273.3 M169.35 M-336.35 M-116.84 M436.33 M 348.1 M Finansman faaliyetlerinden elde edilen nakit 994.98 M1.25 B425.75 M172.13 M294.16 M-305.19 M -333.56 M Serbest nakit akışı -614.96 M-641.69 M-541.27 M104.16 M-8.31 M465.38 M 641.34 M

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

ALNY

Financials

Alnylam Pharmaceuticals, Inc. - Common Stock

Haberler

Are Options Traders Betting on a Big Move in Alnylam Stock?

JPMorgan says large-cap biotech is back as profits and pipelines fuel upside

Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach (NASDAQ:IONS)

These Are The Upcoming Catalysts For Crispr Therapeutics Stock (NASDAQ:CRSP)

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

H.C. Wainwright, güçlü TTR satışları sonrası Alnylam hissesi için tavsiyesini korudu

Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth

Bernstein SocGen, Alnylam’ın hisse hedefini düşürdü

Alnylam Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:ALNY) 2026-04-30

Alnylam 2026 1Ç sunumu: ATTR-CM patlamasıyla tarihi 1 milyar dolarlık gelir eşiği

Alnylam (ALNY) Reports Q1 Earnings: What Key Metrics Have to Say

Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue Estimates